156 related articles for article (PubMed ID: 28285846)
21. Continuous improvement in primary Debulking surgery for advanced ovarian cancer: Do increased complete gross resection rates independently lead to increased progression-free and overall survival?
Tseng JH; Cowan RA; Zhou Q; Iasonos A; Byrne M; Polcino T; Polen-De C; Gardner GJ; Sonoda Y; Zivanovic O; Abu-Rustum NR; Long Roche K; Chi DS
Gynecol Oncol; 2018 Oct; 151(1):24-31. PubMed ID: 30126704
[TBL] [Abstract][Full Text] [Related]
22. Positive DESKTOP and Tian Scores Systems Are Adequate to Predict Optimal (R0) Secondary Debulking Surgery in Ovarian Cancer, But a Negative Score Does Not Preclude Secondary Surgery.
Laga T; Lambrechts S; Laenen A; Van Nieuwenhuysen E; Han SN; Vergote I
Int J Gynecol Cancer; 2018 May; 28(4):721-728. PubMed ID: 29561300
[TBL] [Abstract][Full Text] [Related]
23. Minimal access surgery compared to laparotomy for secondary surgical cytoreduction in patients with recurrent ovarian carcinoma: Perioperative and oncologic outcomes.
Eriksson AGZ; Graul A; Yu MC; Halko A; Chi DS; Zivanovic O; Gardner GJ; Sonoda Y; Barakat RR; Abu-Rustum NR; Leitao MM
Gynecol Oncol; 2017 Aug; 146(2):263-267. PubMed ID: 28527673
[TBL] [Abstract][Full Text] [Related]
24. Thrombocytosis at secondary cytoreduction for recurrent ovarian cancer predicts suboptimal resection and poor survival.
Cohen JG; Tran AQ; Rimel BJ; Cass I; Walsh CS; Karlan BY; Li AJ
Gynecol Oncol; 2014 Mar; 132(3):556-9. PubMed ID: 24423879
[TBL] [Abstract][Full Text] [Related]
25. Primary versus secondary cytoreduction for epithelial ovarian cancer: a paired analysis of tumour pattern and surgical outcome.
Braicu EI; Sehouli J; Richter R; Pietzner K; Lichtenegger W; Fotopoulou C
Eur J Cancer; 2012 Mar; 48(5):687-94. PubMed ID: 21757333
[TBL] [Abstract][Full Text] [Related]
26. Tertiary cytoreduction for recurrent ovarian carcinoma: An updated and expanded analysis.
Manning-Geist BL; Chi DS; Long Roche K; Zivanovic O; Sonoda Y; Gardner GJ; O'Cearbhaill RE; Abu-Rustum NR; Leitao MM
Gynecol Oncol; 2021 Aug; 162(2):345-352. PubMed ID: 34045053
[TBL] [Abstract][Full Text] [Related]
27. Preoperative CA-125 Value as a Predictive Factor for Postoperative Outcome in First Relapse of Platinum-sensitive Serous Ovarian Cancer.
Parashkevova A; Sehouli J; Richter R; Dimitrova D; Braicu EI; Muallem MZ
Anticancer Res; 2018 Aug; 38(8):4865-4870. PubMed ID: 30061261
[TBL] [Abstract][Full Text] [Related]
28. The benefits of low anterior en bloc resection as part of cytoreductive surgery for advanced primary and recurrent epithelial ovarian cancer patients outweigh morbidity concerns.
Park JY; Seo SS; Kang S; Lee KB; Lim SY; Choi HS; Park SY
Gynecol Oncol; 2006 Dec; 103(3):977-84. PubMed ID: 16837030
[TBL] [Abstract][Full Text] [Related]
29. AGO Score As a Predictor of Surgical Outcome at Secondary Cytoreduction in Patients with Ovarian Cancer.
Muallem MZ; Gasimli K; Richter R; Almuheimid J; Nasser S; Braicu EI; Sehouli J
Anticancer Res; 2015 Jun; 35(6):3423-9. PubMed ID: 26026105
[TBL] [Abstract][Full Text] [Related]
30. Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer (SOCceR trial): a multicenter randomised controlled study.
van de Laar R; Zusterzeel PL; Van Gorp T; Buist MR; van Driel WJ; Gaarenstroom KN; Arts HJ; van Huisseling JC; Hermans RH; Pijnenborg JM; Schutter EM; Pelikan HM; Vollebergh JH; Engelen MJ; Inthout J; Kruitwagen RF; Massuger LF
BMC Cancer; 2014 Jan; 14():22. PubMed ID: 24422892
[TBL] [Abstract][Full Text] [Related]
31. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
Chang SJ; Bristow RE; Ryu HS
Ann Surg Oncol; 2012 Dec; 19(13):4059-67. PubMed ID: 22766983
[TBL] [Abstract][Full Text] [Related]
32. Tertiary cytoreductive surgery in recurrent epithelial ovarian cancer: A multicentre MITO retrospective study.
Falcone F; Scambia G; Benedetti Panici P; Signorelli M; Cormio G; Giorda G; Bogliolo S; Marinaccio M; Ghezzi F; Rabaiotti E; Breda E; Casella G; Fanfani F; Di Donato V; Leone Roberti Maggiore U; Greggi S
Gynecol Oncol; 2017 Oct; 147(1):66-72. PubMed ID: 28716306
[TBL] [Abstract][Full Text] [Related]
33. Are There Survival Differences Between Women with Equivalent Residual Disease After Interval Cytoreductive Surgery Compared with Primary Cytoreductive Surgery for Advanced Ovarian and Peritoneal Cancer?
Mysona DP; Ghamande S; She JX; Tran L; Tran P; Rungruang BJ; Chan JK; Bae-Jump V; Gehrig PA
Ann Surg Oncol; 2021 Jul; 28(7):3605-3615. PubMed ID: 33155151
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data.
Polterauer S; Vergote I; Concin N; Braicu I; Chekerov R; Mahner S; Woelber L; Cadron I; Van Gorp T; Zeillinger R; Castillo-Tong DC; Sehouli J
Int J Gynecol Cancer; 2012 Mar; 22(3):380-5. PubMed ID: 22266934
[TBL] [Abstract][Full Text] [Related]
35. Impact of hospital surgical volume on complete gross resection (CGR) rates following primary debulking surgery for advanced stage epithelial ovarian carcinoma.
Nasioudis D; Kahn R; Chapman-Davis E; Frey MK; Caputo TA; Witkin SS; Holcomb K
Gynecol Oncol; 2019 Aug; 154(2):401-404. PubMed ID: 31160074
[TBL] [Abstract][Full Text] [Related]
36. [Recurrent ovarian cancer--qualification and results of surgical treatment].
Derlatkal P; Grabowska-Derlatka L; Jalinik K; Danska-Bidzińska A
Ginekol Pol; 2015 Dec; 86(12):902-6. PubMed ID: 26995939
[TBL] [Abstract][Full Text] [Related]
37. Predictive value of the Age-Adjusted Charlson Comorbidity Index on perioperative complications and survival in patients undergoing primary debulking surgery for advanced epithelial ovarian cancer.
Suidan RS; Leitao MM; Zivanovic O; Gardner GJ; Long Roche KC; Sonoda Y; Levine DA; Jewell EL; Brown CL; Abu-Rustum NR; Charlson ME; Chi DS
Gynecol Oncol; 2015 Aug; 138(2):246-51. PubMed ID: 26037900
[TBL] [Abstract][Full Text] [Related]
38. Minimally invasive secondary cytoreduction plus HIPEC versus open surgery plus HIPEC in isolated relapse from ovarian cancer: a retrospective cohort study on perioperative outcomes.
Fagotti A; Costantini B; Gallotta V; Cianci S; Ronsini C; Petrillo M; Pacciani M; Scambia G; Fanfani F
J Minim Invasive Gynecol; 2015; 22(3):428-32. PubMed ID: 25461683
[TBL] [Abstract][Full Text] [Related]
39. Secondary cytoreductive surgery - viable treatment option in the management of platinum-sensitive recurrent ovarian cancer.
Felsinger M; Minar L; Weinberger V; Rovny I; Zlamal F; Bienertova-Vasku J
Eur J Obstet Gynecol Reprod Biol; 2018 Sep; 228():154-160. PubMed ID: 29957400
[TBL] [Abstract][Full Text] [Related]
40. Patterns of Recurrence and Clinical Outcome of Patients With Stage IIIC to Stage IV Epithelial Ovarian Cancer in Complete Response After Primary Debulking Surgery Plus Chemotherapy or Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery: An Italian Multicenter Retrospective Study.
Gadducci A; Cosio S; Zizioli V; Notaro S; Tana R; Panattoni A; Sartori E
Int J Gynecol Cancer; 2017 Jan; 27(1):28-36. PubMed ID: 27870700
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
